AIRCURRENTS: Modeling a Modern- Day Spanish Flu Pandemic
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Avian Influenza “Bird Flu”
AVIAN FLU CONCERNS ESCALATE WORLDWIDE Louise Shimmel Avian influenza (“bird flu” as it is sometimes called in the press) is making its way into the news almost daily and causing worry among global health authorities, including the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and the National Institute of Allergy and Infectious Diseases (NIAID). Avian influenzas are not new; they come in many types with widely varying levels of disease-causing capability. Definition: Influenza type A viruses, which include human and avian flu viruses, are categorized by H and N components, which denote specific types of proteins on their surface. The H component governs the ability of the virus to bind to and enter cells, which become virus-making factories. The N component governs the release of the newly made viruses from the animal host cell." [Reuters alertnet, 16 Nov 2005, edited.] There are 16 different HA subtypes and 9 different NA in type A influenza viruses. "There are only three known A subtypes of human flu viruses (H1N1, H1N2, and H3N2). When discussing “bird flu” we are talking about the influenza A subtypes chiefly found in birds. They do not usually infect humans, even though we know they can. [Fact Sheet, Avian Influenza, William T. Ferrier, DVM - prepared for falconers.] The virus making headlines is a specific subtype-H5N1-but there is more than one form of H5N1, specifically high- and low-pathogenic strains. The high-pathogenic form of H5N1 is the one in Asia that is causing global concern. There has been a low-pathogenic form of H5N1 found in migrating wild birds in Canada this fall, which is no cause for alarm. -
Dectova, INN-Zanamivir
28 February 2019 EMA/CHMP/851480/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report DECTOVA International non-proprietary name: zanamivir Procedure No. EMEA/H/C/004102/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 12 2.1. Problem statement ............................................................................................. 12 2.1.1. Disease or condition ......................................................................................... 12 2.1.2. Epidemiology .................................................................................................. 12 2.1.3. Biologic features ............................................................................................. -
Influenza Vaccine Directive
FAQS: INFLUENZA VACCINE DIRECTIVE FLU VACCINE UPDATES: Flu shots are now required for all staff working in healthcare settings in Alameda County and Berkeley, as recently ordered in a joint mandate by public health officers for Alameda County. This new mandate notes that with the flu season overlapping the COVID-19 pandemic, the risk is higher for health systems to be overwhelmed by patients with critical respiratory illness. Although there is no vaccine yet for COVID-19, the flu shot remains a safe and effective way to minimize the impacts of flu season and thousands of related doctor and hospital visits. Under Alameda County’s new order, all workers in healthcare settings must receive a flu vaccine to help protect themselves, teammates, patients and the wider community. Within our organization, all employees who work in Alameda County and have direct patient contact, must receive a flu shot no later than December 3, 2020. The new mandate specifies that you may only decline a flu shot if you provide a signed certification from your primary care provider stating that you have a medical condition that makes it unsafe to receive the flu vaccine. Masking is not an acceptable alternative to receiving the flu shot. If you haven’t yet received your flu shot, and you work in an Epic Care location within Alameda County, you must receive a flu vaccine on or before December 3, 2020. Flu vaccines are available at your local pharmacy, your doctor’s office, or Epic Care (while supplies last). If you are unable to obtain a flu vaccine through Epic Care, and you instead receive it from a different pharmacy or doctor’s office, the out of pocket cost of the vaccine will be reimbursed to you with a valid receipt for payment. -
Novel H1N1 Influenza Updated Key Points June 11, 2009 • On
Novel H1N1 Influenza Updated Key Points June 11, 2009 • On June 11, 2009, the World Health Organization (WHO) raised the worldwide pandemic alert level to Phase 6. • Designation of this phase indicates that a global pandemic is underway. • There are now community level outbreaks ongoing in other parts of the world. • State and international borders don’t matter at this point. The bottom line is that this new virus is among us all. • While U.S. influenza surveillance systems indicate that overall flu activity is decreasing in the United States, novel H1N1 outbreaks are ongoing in different parts of the U.S., in some cases with intense activity. • In the United States, this virus has been spreading efficiently from person-to-person since April and, as we have been saying for some time, we do expect that we will see more cases, more hospitalizations and more deaths from this virus. • Because there is already widespread novel H1N1 disease in the United States, the WHO Phase 6 declaration does not change what the United States is currently doing to keep people healthy and protected from the virus. • Thus there is no change to CDC’s recommendations for individuals and communities. • WHO’s decision to raise the pandemic alert level to Phase 6 is a reflection of epidemiological changes in other parts of the world and not a reflection of any change in the novel H1N1 virus or associated illness. • At this time, most of the people who have become ill with novel H1N1 in the United States have not become seriously ill and have recovered without hospitalization. -
Chapter 19 Influenza
Chapter 19: Influenza October 2020 19 Influenza Influenza The disease Influenza is an acute viral infection of the respiratory tract. There are three types of influenza virus: A, B and C. Influenza A and influenza B are responsible for most clinical illness. Influenza is highly infectious with a usual incubation period of one to three days. The disease is characterised by the sudden onset of fever, chills, headache, myalgia and extreme fatigue. Other common symptoms include a dry cough, sore throat and stuffy nose. For otherwise healthy individuals, influenza is an unpleasant but usually self-limiting disease with recovery usually within two to seven days. The illness may be complicated by (and may present as) bronchitis, secondary bacterial pneumonia or, in children, otitis media. Influenza can be complicated more unusually by meningitis, encephalitis or meningoencephalitis. The risk of serious illness from influenza is higher amongst children under six months of age (Poehling et al., 2006; Ampofo et al., 2006; Coffin et al., 2007; Zhou et al, 2012), older people (Thompson et al., 2003 and 2004; Zhou et al, 2012) and those with underlying health conditions such as respiratory or cardiac disease, chronic neurological conditions, or immunosuppression and pregnant women (Neuzil et al., 1998; O’Brien et al., 2004; Nicoll et al., 2008 and Pebody et al., 2010). Influenza during pregnancy may also be associated with perinatal mortality, prematurity, smaller neonatal size and lower birth weight (Pierce et al., 2011; Mendez-Figueroa et al., 2011). Although primary influenza pneumonia is a rare complication that may occur at any age and carries a high case fatality rate (Barker and Mullooly, 1982), it was seen more frequently during the 2009 pandemic and the following influenza season. -
Flu Season Which Can Last As Late As May
What Everyone Should Know About Seasonal Flu and the Seasonal Flu Vaccine Seasonal flu is not just a really bad cold. The flu is a contagious illness that affects the nose, throat, lungs and other parts of the body. It can spread quickly from one person to another. It can cause mild to severe illness, and at times can lead to death. Flu viruses are spread mainly from person to person through coughing or sneezing by people with influenza. Sometimes people may become infected by touching something - such as a surface or object - with flu viruses on it and then touching their mouth or nose. Every year in the U.S., on average: • 5% to 20% of the population gets the flu, • More than 200,000 people are hospitalized from seasonal flu complications and; • About 23,500 (and as high as about 48,000) people die from seasonal flu. The best way to prevent seasonal flu is by getting a flu shot or flu spray vaccination every year. When to get vaccinated against seasonal flu: Yearly flu vaccination should begin in September, or as soon as vaccine is available, and continue throughout the flu season which can last as late as May. This is because the timing and duration of flu seasons vary. While flu season can begin early as October, most of the time seasonal flu activity peaks in January, February or later. http://www.cdc.gov/flu/keyfacts.htm You can't get flu from getting a flu vaccine! The flu vaccine does not give you the flu. -
Antiviral Drugs for Influenza Prevention and Treatment
Antiviral Drugs for Influenza Prevention and Treatment Antiviral drugs are not a substitute for influenza (flu) vaccination. However, prescription antiviral medications play an important role in preventing and controlling the spread of influenza. These medications are a critical component of the U.S. Centers for Disease Control and Prevention (CDC) “Take 3” Actions to Fight the Flu. Take 3 urges everyone age 6 months and older to get vaccinated, follow good hand hygiene and cough/sneeze etiquette, and to take antiviral medications if they are prescribed.1 Influenza antiviral drugs are available to treat and prevent influenza: For Treatment: Antiviral drugs can reduce influenza symptoms, shorten the duration of illness, and prevent serious complications, like pneumonia, if taken within 48 hours of symptom onset.1,2 For Prevention: Antiviral drugs may also be prescribed to help prevent influenza in individuals who have been exposed to the virus. Antiviral drugs are about 70 to 90 percent effective when used as directed for prevention.3 For the 2014-15 flu season, CDC recommends use of either oseltamivir (Tamiflu®) or zanamivir (Relenza®) for treatment and prevention of influenza.2 Oseltamivir and zanamivir are dosed and administered differently, and are recommended for patients based on age and risk factors. A healthcare professional is best equipped to make an appropriate flu diagnosis and determine if antiviral treatment is recommended. More information about antiviral treatments is available at http://www.cdc.gov/flu/antivirals. Time Is of the Essence With antiviral therapy, timing is critical. A healthcare professional should be contacted at the first sign of influenza symptoms such as sudden onset of fever, aches, chills, and tiredness (for more information, see the fact sheet “Understanding Influenza”). -
Efficacy of Baloxavir Marboxil on Household Transmission Of
Umemura et al. Journal of Pharmaceutical Health Care and Sciences (2020) 6:21 https://doi.org/10.1186/s40780-020-00178-4 RESEARCH ARTICLE Open Access Efficacy of baloxavir marboxil on household transmission of influenza infection Takumi Umemura1,2* , Yoshikazu Mutoh2, Takato Kawamura1, Masayuki Saito1, Takahito Mizuno1, Aiko Ota1, Koji Kozaki1, Tetsuya Yamada1, Yoshiaki Ikeda3 and Toshihiko Ichihara2 Abstract Background: Baloxavir marboxil (baloxavir) is a new anti-influenza virus agent that is comparable to oseltamivir phosphate (oseltamivir). Since the efficacy of baloxavir in preventing household transmission of influenza is not well established, we compared the secondary household influenza virus transmission rates between patients on baloxavir vs oseltamivir. Methods: Between October 2018 and March 2019, we enrolled index patients (diagnosed with influenza and treated with baloxavir or oseltamivir) and household members. The secondary attack rate of household members was compared between index patients treated with baloxavir vs oseltamivir. Risk factors of household transmission were determined using multivariate logistic analyses. Results: In total, 169 index patients with influenza type A were enrolled. The median age was 27.0 (interquartile range; 11–57) years. The number of index patients treated with baloxavir and oseltamivir was 49 and 120, respectively. The secondary attack rate was 9.0% (95% confidence interval [CI]: 4.6–15.6) in the baloxavir group and 13.5% (95% CI: 9.8–17.9) in the oseltamivir group. In the multivariate analysis, independent risk factors were 0–6 years of age (odds ratio [OR] 2.78, 95% CI: 1.33–5.82, p < 0.01) and not being on baloxavir treatment. -
View Full Issue
Volume 31, Issue 2, December 2015 ISSN 0204-8809 ACTA MICROBIOLOGICA BULGARICA Bulgarian Society for Microbiology Union of Scientists in Bulgaria Acta Microbiologica Bulgarica The journal publishes editorials, original research works, research reports, reviews, short communications, letters to the editor, historical notes, etc from all areas of microbiology An Official Publication of the Bulgarian Society for Microbiology (Union of Scientists in Bulgaria) Volume 31 / 2 (2015) Editor-in-Chief Angel S. Galabov Press Product Line Sofia Editor-in-Chief Angel S. Galabov Editors Maria Angelova Hristo Najdenski Editorial Board I. Abrashev, Sofia S. Aydemir, Izmir, Turkey L. Boyanova, Sofia E. Carniel, Paris, France M. Da Costa, Coimbra, Portugal E. DeClercq, Leuven, Belgium S. Denev, Stara Zagora D. Fuchs, Innsbruck, Austria S. Groudev, Sofia I. Iliev, Plovdiv A. Ionescu, Bucharest, Romania L. Ivanova, Varna V. Ivanova, Plovdiv I. Mitov, Sofia I. Mokrousov, Saint-Petersburg, Russia P. Moncheva, Sofia M. Murdjeva, Plovdiv R. Peshev, Sofia M. Petrovska, Skopje, FYROM J. C. Piffaretti, Massagno, Switzerland S. Radulovic, Belgrade, Serbia P. Raspor, Ljubljana, Slovenia B. Riteau, Marseille, France J. Rommelaere, Heidelberg, Germany G. Satchanska, Sofia E. Savov, Sofia A. Stoev, Kostinbrod S. Stoitsova, Sofia T. Tcherveniakova, Sofia E. Tramontano, Cagliari, Italy A. Tsakris, Athens, Greece F. Wild, Lyon, France Vol. 31, Issue 2 December 2015 ACTA MICROBIOLOGICA BULGARICA CONTENTS Review Articles Biohydrometallurgy in Bulgaria - Achievements and -
Oseltamivir, Zanamivir and Amantadine in the Prevention of Influenza: a Systematic Review
Journal of Infection (2011) 62,14e25 www.elsevierhealth.com/journals/jinf Oseltamivir, zanamivir and amantadine in the prevention of influenza: A systematic review Rachel J. Jackson a,*, Katy L. Cooper a, Paul Tappenden a, Angie Rees b, Emma L. Simpson a, Robert C. Read c, Karl G. Nicholson d a Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK b School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK c Department of Infection & Immunity, School of Medicine, University of Sheffield, Beech Hill Rd, Sheffield, S10 2RX, UK d Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, LE2 7LX, UK Accepted 5 October 2010 Available online 13 October 2010 KEYWORDS Summary Objective: To systematically review evidence relating to the clinical efficacy of Influenza; oseltamivir, zanamivir and amantadine in the prevention of influenza. Prophylaxis; Methods: RCTs evaluating these interventions in seasonal prophylaxis and post-exposure pro- Prevention; phylaxis were identified using electronic bibliographic databases and handsearching of Amantadine; retrieved articles. Oseltamivir; Results: Oseltamivir was effective in preventing symptomatic laboratory-confirmed influenza Zanamivir; (SLCI) in seasonal prophylaxis in healthy adults and at-risk elderly subjects and in post-expo- Neuraminidase sure prophylaxis within households of mixed composition. Post-exposure prophylaxis using inhibitor; oseltamivir for paediatric contacts was observed to prevent SLCI. Zanamivir prevented M2 inhibitor; SLCI in seasonal prophylaxis in healthy adults, at-risk adults and adolescents and in post-expo- Systematic review sure prophylaxis within mixed households, with a trend for seasonal and post-exposure preven- tative effects in elderly subjects. -
State of Connecticut-Department of Social Services
STATE OF CONNECTICUT-DEPARTMENT OF SOCIAL SERVICES 55 FARMINGTON AVENUE, HARTFORD, CONNECTICUT 06105 Connecticut AIDS Drug Assistance Program (CADAP) Formulary Effective: March 1, 2018 Antiretroviral: Multiclass Single Tablet Regimens Abacavir/ Lamivudine/ Dolutegravir Efavirenz/Emtricitabine/ Tenofovir Disoproxil Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir ( Triumeq ) Fumarate (Atripla ) Disoproxil Fumarate (Stribild ) Bictegravir/ Emtricitabine/Tenofovir Elvitegravir, Cobicistat, Emtricitabine/Tenofovir Emtricitabine/Rilpivirine/ Tenofovir Disoproxil Alafenamide (Biktarvy) Alafenamide (Genvoya ) Fumarate (Complera ) Antiretroviral: Combination Medications Abacavir /Lamivudine (Epzicom) Atazanavir/Cobicistat (Evotaz) Lamivudine/Zidovudine (Combivir) Abacavir/Lamivudine/ Zidovudine Darunavir/Cobicistat (Prezcobix) Lopinavir/Ritonavir (Kaletra) (Trizivir) Emtricitabine/Tenofovir (Truvada) Antiretrovirals: Nucleoside Reverse Transcriptase Inhibitor (NRTIs) Medications Abacavir (Ziagen) Emtricitabine (Emtriva) Tenofovir DF (Viread) Didanosine (ddI, Videx, Videx EC) Lamivudine (3TC, Epivir, Epivir HBV ) Zidovudine (AZT, Retrovir ) Stavudine (Zerit) Antiretrovirals: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTIs) Medications Delavirdine Mesylate (Rescriptor) Etravirine (Intelence) Rilpivirine (Edurant) Efavirenz (Sustiva) Nevirapine ( Viramune/Viramune XR ) Antiretrovirals: Protease Inhibitor (PIs) Medications Atazanavir Sulfate (Reyataz) Indinavir (Crixivan) Ritonavir (Norvir) Darunavir (Prezista) Lopinavir/Ritonavir (Kaletra) -
Peramivir (Rapivab®) National Drug Monograph March 2015
Peramivir (RAPIVAB)Monograph Peramivir (Rapivab®) National Drug Monograph March 2015 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a comprehensive drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information Description/Mechanism of Peramivir is a neuraminidase inhibitor with activity against influenza A and B Action viruses. Indication(s) Under Review in Peramivir is indicated for the treatment of acute, uncomplicated influenza in this document (may include patients 18 years and older who have been symptomatic for no more than two off label) days. Please note the prescribing information states the following limitations of use: • Efficacy based on clinical trials in which the predominant influenza virus type was influenza A; a limited number of subjects infected with influenza B virus were enrolled. • Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. • Efficacy could not be established in patients with serious influenza requiring hospitalization. Dosage Form(s) Under 200mg single-use 20 mL vial (10mg/mL) for injection Review REMS REMS No REMS Postmarketing Requirements Pregnancy Rating Pregnancy Category C Executive Summary Efficacy Approval of peramivir was based upon a single pivotal Phase 2 trial, two supporting Phase 2 trials, and one supporting Phase 3 trial (refer to Table 1) evaluating adult patients with acute, uncomplicated influenza who presented within 48 hours of symptom onset; all trials were randomized, multicentered, double-blind, and placebo-controlled.